pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Triple Negative Breast Cancer
Conditions
Metastatic Triple Negative Breast Cancer
Trial Timeline
Oct 13, 2015 → Nov 10, 2020
NCT ID
NCT02555657About pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbine
pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbine is a phase 3 stage product being developed by Merck for Metastatic Triple Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02555657. Target conditions include Metastatic Triple Negative Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Triple Negative Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02555657 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Triple Negative Breast Cancer